News Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 01:32:08 2024-12-03 pm EST			5-day change	1st Jan Change
59.12 ^USD	-1.38%		+0.82%	+15.42%

02:00pm	Bristol-Myers Squibb Company Presents at Citi's 2024 Global Healthcare Conference, Dec-03-2024 08:00 AM
02:00pm	AI Proteins, Inc. Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued Up to $400 Million	CI

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Bristol-Myers Squibb Company Presents at Citi's 2024 Global Healthcare Conference, Dec-03-2024 08:00 AM	08:00am
AI Proteins, Inc. Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued Up to $400 Million	08:00am	CI
Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List	Nov. 29	MT
Bristol Myers Squibb to Participate in Citi’s 2024 Global Healthcare Conference	Nov. 26	BU
Bernstein Adjusts Price Target on Bristol-Myers Squibb to $62 From $56, Keeps Market Perform Rating	Nov. 25	MT
Wall Street warms to AI's glow	Nov. 22
Bristol Myers Squibb's Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms	Nov. 20	AQ
Bristol Myers: presents new data to ASH	Nov. 19	CF
Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms	Nov. 19	BU
Bristol Myers Squibb?s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms	Nov. 19	CI
Bristol-Myers Squibb Company Presents at Jefferies London Healthcare Conference 2024, Nov-19-2024 09:30 AM	Nov. 19
Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $60 From $52, Maintains Equalweight	Nov. 18	MT
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors	Nov. 18	AQ
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo plus Yervoy for the First-Line Treatment of Adult Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer	Nov. 18	AQ
HSBC Adjusts Bristol-Myers Squibb Price Target to $58 From $50, Maintains Hold Rating	Nov. 15	MT
Bristol-Myers Says European Committee Recommends Approval of Opdivo-Yervoy Combination Therapy for Colorectal Cancer	Nov. 15	MT
Bristol Myers Squibb's Augtyro Recommended for EU Approval	Nov. 15	MT
Bristol Myers: positive opinion from CHMP for Opdivo	Nov. 15	CF
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer	Nov. 15	BU
Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug	Nov. 15	DJ
Bristol-Myers Says European Committee Recommends Approval of Repotrectinib	Nov. 15	MT
Bristol Myers: positive opinion for repotrectinib in U	Nov. 15	CF
Bristol-Myers Squibb Faces $6.7 Billion Lawsuit in Renewed Cancer Drug Delay Case	Nov. 15	MT
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors	Nov. 15	BU
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors	Nov. 15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST